Trial Profile
A phase II study to determine the efficacy and safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha protocol CSTI5710110 (Novartis)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Sep 2019
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia; Myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Novartis
- 09 Jan 2006 New trial record.